| gap-landscape-3e14a6 | Gap in Human Brain Cell Types: Layer 5A Corticostriatal Neuron Selective Vulnera | proposed | 0.64 | 0.64 | 2026-04-25 | 0 | | human-brain-cell-types |
| gap-landscape-24d703 | Gap in Human Brain Cell Types: Cross Atlas Harmonization For Rare Cell Types (<0 | proposed | 0.64 | 0.64 | 2026-04-25 | 0 | | human-brain-cell-types |
| gap-landscape-e695fb | Gap in Synthetic Biology Lineage Tracing: Crispr Delivery Systems For In Vivo Th | proposed | 0.80 | 0.80 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-landscape-3761b9 | Gap in Synthetic Biology Lineage Tracing: Next Generation Base Editor Variants W | proposed | 0.80 | 0.80 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-landscape-d03182 | Gap in Synthetic Biology Lineage Tracing: Zebrafish Developmental Lineage At Sin | proposed | 0.80 | 0.80 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-landscape-d4e46e | Gap in Synthetic Biology Lineage Tracing: Lineage Atlas Cross Platform Harmoniza | proposed | 0.80 | 0.80 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-landscape-6254b2 | Gap in Human Brain Cell Types: Human Specific Chandelier Cell Molecular Identity | proposed | 0.64 | 0.64 | 2026-04-25 | 0 | | human-brain-cell-types |
| gap-landscape-690e80 | How to integrate lineage recording with spatial transcriptomics? | proposed | 0.84 | 0.84 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-landscape-469541 | How to achieve single-cell resolution in whole-organism lineage at scale? | proposed | 0.84 | 0.84 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-synthetic-bio-ce | Gap in synthetic-biology-lineage-tracing: CRISPR Genome-wide Screens | open | 0.50 | 0.00 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-synthetic-bio-ce | Gap in synthetic-biology-lineage-tracing: CRISPR Delivery Systems | open | 0.50 | 0.00 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-synthetic-bio-ce | Gap in synthetic-biology-lineage-tracing: Prime Editing Systems & Applications | open | 0.50 | 0.00 | 2026-04-25 | 0 | | synthetic-biology-lineage-tracing |
| gap-crispr-sma-hunti | CRISPR-based gene therapies for monogenic neurological disorders: SMA, Huntingto | resolved | 0.85 | 0.00 | 2026-04-18 | 0 | | neurodegeneration |
| gap-ferroptosis-als- | Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron | partially_addressed | 0.85 | 0.00 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | What are the druggable differences between C1q binding interfaces for neuronal m | open | 0.75 | 0.65 | 2026-04-17 | 0 | | molecular-biology |
| gap-debate-20260417- | Can C1q-mediated synaptic pruning be blocked without impairing Aβ clearance func | open | 0.80 | 0.72 | 2026-04-17 | 0 | | immunology |
| gap-debate-20260417- | Is C1q elevation in human AD causally pathogenic or an epiphenomenon of neuroinf | open | 0.85 | 0.72 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | Does C1q function differ based on subcellular localization or binding partner id | partially_addressed | 0.90 | 0.71 | 2026-04-17 | 1 | 2026-04-25 | neurodegeneration |
| gap-debate-20260417- | What biomarkers can distinguish Aβ-dependent versus Aβ-independent phases of tau | open | 0.85 | 0.72 | 2026-04-17 | 0 | | biomarker-development |
| gap-debate-20260417- | Can lysosomal dysfunction convert tau into proteolysis-resistant conformations t | open | 0.79 | 0.70 | 2026-04-17 | 0 | | cell-biology |
| gap-debate-20260417- | What determines the bidirectional versus unidirectional nature of Aβ-tau synergi | open | 0.82 | 0.70 | 2026-04-17 | 0 | | molecular-biology |
| gap-debate-20260417- | Does tau dendritic missorting persist independently after Aβ clearance, maintain | partially_addressed | 0.88 | 0.72 | 2026-04-17 | 1 | 2026-04-25 | neurodegeneration |
| gap-debate-20260417- | What drives presynaptic glycosyltransferase dysregulation in early AD pathogenes | open | 0.70 | 0.65 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | How does SV2A glycosylation status predict levetiracetam treatment response in A | open | 0.80 | 0.66 | 2026-04-17 | 0 | | translational-medicine |
| gap-debate-20260417- | Which specific N-glycosylation sites on SV2A are functionally critical for synap | open | 0.75 | 0.62 | 2026-04-17 | 0 | | molecular-neurobiology |
| gap-debate-20260417- | Does SV2A hypoglycosylation cause or result from hippocampal hyperexcitability i | open | 0.85 | 0.69 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | Which TLR4 downstream pathways specifically promote α-synuclein nucleation versu | open | 0.75 | 0.68 | 2026-04-17 | 0 | | immunology |
| gap-debate-20260417- | Does vagal denervation prevent or accelerate gut-to-brain α-synuclein propagatio | open | 0.85 | 0.72 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | What determines AhR ligand specificity for TMAO versus other gut metabolites in | open | 0.80 | 0.61 | 2026-04-17 | 0 | | molecular-biology |
| gap-debate-20260417- | Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects | partially_addressed | 0.90 | 0.65 | 2026-04-17 | 1 | 2026-04-24 | neurodegeneration |
| gap-debate-20260417- | Do TREM2 activation states define distinct amyloid clearance thresholds requirin | open | 0.79 | 0.70 | 2026-04-17 | 0 | | immunology |
| gap-debate-20260417- | What is the temporal relationship between amyloid threshold achievement and meas | open | 0.75 | 0.71 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ | investigating | 0.88 | 0.64 | 2026-04-17 | 1 | 2026-04-25 | neurodegeneration |
| gap-debate-20260417- | What is the causal molecular pathway connecting extracellular amyloid clearance | open | 0.82 | 0.70 | 2026-04-17 | 0 | | molecular-biology |
| gap-debate-20260417- | Can lysosomal volume-sensing dysfunction serve as a biomarker for LRRK2-linked n | open | 0.75 | 0.68 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | How do LRRK2 kinase inhibitors rescue lysosomal phenotypes - through volume-sens | open | 0.80 | 0.70 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | What is the dynamic range and kinetics of LRRK2 substrate phosphorylation during | resolved | 0.85 | 0.69 | 2026-04-17 | 0 | | molecular-biology |
| gap-debate-20260417- | Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate bas | partially_addressed | 0.90 | 0.70 | 2026-04-17 | 1 | 2026-04-24 | neurodegeneration |
| gap-debate-20260417- | Can pharmacological SREBP2 stabilization differentially rescue APOE4 versus APOE | open | 0.75 | 0.69 | 2026-04-17 | 0 | | pharmacology |
| gap-debate-20260417- | How does microglial cholesterol accumulation mechanistically prime NLRP3 inflamm | open | 0.80 | 0.70 | 2026-04-17 | 0 | | immunology |
| gap-debate-20260417- | Is enhanced cholesterol synthesis in APOE4 carriers compensatory or directly pat | open | 0.85 | 0.70 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retenti | partially_addressed | 0.90 | 0.69 | 2026-04-17 | 1 | 2026-04-24 | molecular-biology |
| gap-debate-20260417- | Do senescent oligodendrocyte precursors contribute to white matter degeneration | open | 0.73 | 0.71 | 2026-04-17 | 0 | | neurobiology |
| gap-debate-20260417- | What is the therapeutic window for senolytic intervention before irreversible ne | open | 0.79 | 0.69 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | Which senolytic compounds achieve therapeutic CNS concentrations while maintaini | open | 0.82 | 0.68 | 2026-04-17 | 0 | | pharmacology |
| gap-debate-20260417- | Does pericyte senescence drive BBB breakdown or result from neurodegeneration as | partially_addressed | 0.88 | 0.69 | 2026-04-17 | 1 | 2026-04-25 | neurodegeneration |
| gap-debate-20260417- | How do gC1qR surface expression levels affect microglial C1q signaling in neurod | open | 0.65 | 0.68 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | Can kinase inhibitors achieve therapeutic effects through off-target complement | open | 0.70 | 0.71 | 2026-04-17 | 0 | | pharmacology |
| gap-debate-20260417- | What is the structural basis for small molecule recognition by complement protei | open | 0.75 | 0.69 | 2026-04-17 | 0 | | structural-biology |
| gap-debate-20260417- | Does Alectinib truly bind C1q directly with high affinity, or is this an experim | partially_addressed | 0.90 | 0.55 | 2026-04-17 | 0 | | molecular-biology |